It has been about a month since the last earnings report for Vertex Pharmaceuticals (VRTX). Shares have added about 2.7% in that time frame, outperforming the S&P 500. But investors have to be ...

Vertex Pharmaceuticals VRTX reported strong second-quarter results driven by the continued robust uptake of its cystic fibrosis triple-combination therapy, Trikafta/Kaftrio. Product revenue of $2.49 ...

Vertex VRTX reported third-quarter results highlighted by strong uptake of its cystic fibrosis triple combination therapy, Trikafta/Kaftrio, in the United States and internationally. Quarterly product ...

Vertex Pharmaceuticals Incorporated VRTX stock has risen 9.2% in the past three months. However, the stock has significantly ...

We expect Vertex Pharmaceuticals VRTX to surpass expectations when it reports its third-quarter 2025 results on Nov. 3, after market close. The Zacks Consensus Estimate for the to-be-reported ...

Vertex Pharmaceuticals Incorporated's stock has shown resilience, recovering from dips and maintaining a strong long-term growth trajectory, driven by its robust CF franchise and new product approvals ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor ...

-More than 1,200 children are newly eligible for a medicine that could treat the underlying cause of their disease- About Cystic Fibrosis Cystic fibrosis (CF) is a rare, life-shortening genetic ...

Vertex Pharmaceuticals generates strong sales growth from Trikafta/Kaftrio, which still has more untapped potential. Occidental Petroleum's business benefited from rising oil prices, and its profits ...

Vertex Pharmaceuticals Incorporated VRTX is scheduled to release fourth-quarter and full-year 2023 results on Feb 5, after market close. The company has an impressive earnings surprise history, ...